In animal models, IL-1 receptor antagonists and NLRP3 inhibitors like MCC950 have shown promise in reducing inflammation and slowing disease progression, paving the way for clinical trials in human CSOM patients (71, 106). This evidence concerns the gene NLRP3 and chronic purulent otitis media.